Trials / Completed
CompletedNCT00067119
Aggrenox Prevention of Access Stenosis
Effect of Dipyridamole Plus Aspirin on Hemodialysis Graft Patency
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 649 (actual)
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · NIH
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of the study is to determine whether Aggrenox (Boehringer-Ingelheim) prolongs primary unassisted patency in newly created arteriovenous grafts. This record previously included information for both the GRAFT and FISTULA trials.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aggrenox | |
| DRUG | Placebo |
Timeline
- Start date
- 2003-01-01
- Primary completion
- 2008-01-31
- Completion
- 2008-01-31
- First posted
- 2003-08-13
- Last updated
- 2017-09-19
Locations
9 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT00067119. Inclusion in this directory is not an endorsement.